Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing

References

• Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):542–544.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 Jan;21(1):39–51.
   PubMed Web of Science ®Google Scholar
• Ai J, Zhang Y, Zhang H, et al. Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study. Emerg Microbes Infect. 2022;11(1):639–647.
   PubMed Web of Science ®Google Scholar
• Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Jun;21(6):803–812.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020 Dec 10;383(24):2320–2332.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. N Engl J Med. 2022 May 4.
   Google Scholar
• Kreier F. Ten billion COVID vaccinations: world hits new milestone. Nature. 2022 Jan 31. doi: 10.1038/d41586-022-00285--2. Online ahead of print.
   Google Scholar
• Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study. Br Med J. 2021 Aug 20;374:n2015.
   PubMed Web of Science ®Google Scholar
• Premikha M, Chiew CJ, Wei WE, et al. Comparative effectiveness of mRNA and inactivated whole virus vaccines against COVID-19 infection and severe disease in Singapore. Clin Infect Dis. 2022 Oct 12;75(8):1442–1445.
   PubMed Web of Science ®Google Scholar
• Acevedo ML, Gaete-Argel A, Alonso-Palomares L, et al. Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 lambda in Chile. Nat Microbiol. 2022 Apr;7(4):524–529.
   PubMed Web of Science ®Google Scholar
• Yan VKC, Wan EYF, Ye X, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study. Emerg Microbes Infect. 2022;11(1):2304–2314.
   PubMed Web of Science ®Google Scholar
• Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018 Jan;18(1):35–45.
   PubMed Web of Science ®Google Scholar
• Ren X, Wen W, Fan X, et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell. 2021 Apr 1;184(7):1895–1913.e19.
   PubMed Web of Science ®Google Scholar
• Arunachalam PS, Scott MKD, Hagan T, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021 Aug;596(7872):410–416.
   PubMed Web of Science ®Google Scholar
• Cao Q, Wu S, Xiao C, et al. Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization. Cell Discov. 2021 Aug 10;7(1):64.
   PubMed Web of Science ®Google Scholar
• Xie T, Lu S, He Z, et al. Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. Signal Transduct Target Ther. 2022 Feb 25;7(1):61.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang J, Xu J, et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov. 2021 Oct 26;7(1):99.
   PubMed Web of Science ®Google Scholar
• World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013 Nov 27;310(20):2191–2194.
   PubMed Web of Science ®Google Scholar
• Corkum CP, Ings DP, Burgess C, et al. Immune cell subsets and their gene expression profiles from human PBMC isolated by vacutainer cell preparation tube (CPT™) and standard density gradient. BMC Immunol. 2015 Aug 26;16:48.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu X, Liu Q, et al. Serological reactivity of inactivated SARS-CoV-2 vaccine based on an S-RBD neutralizing antibody assay. Int J Infect Dis. 2022 Apr;117:169–173.
   PubMed Web of Science ®Google Scholar
• Shi J, Tong R, Zhou M, et al. Circadian nuclear receptor Rev-erbα is expressed by platelets and potentiates platelet activation and thrombus formation. Eur Heart J. 2022 Jun 21;43(24):2317–2334.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu Y, Liu D, et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. Cell Res. 2021 Nov;31(11):1215–1217.
   PubMed Web of Science ®Google Scholar
• Kapellos TS, Bonaguro L, Gemünd I, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 2019;10:2035.
   PubMed Web of Science ®Google Scholar
• Lee S, Ryu JH. Influenza viruses: innate immunity and mRNA vaccines. Front Immunol. 2021;12:710647.
   PubMed Web of Science ®Google Scholar
• Fujimura K, Oyamada A, Iwamoto Y, et al. CD4 t cell-intrinsic IL-2 signaling differentially affects Th1 and Th17 development. J Leukoc Biol. 2013 Aug;94(2):271–279.
   PubMed Web of Science ®Google Scholar
• Li-Weber M, Krammer PH. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat Rev Immunol. 2003 Jul;3(7):534–543.
   PubMed Web of Science ®Google Scholar
• Sureshchandra S, Lewis SA, Doratt BM, et al. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine. JCI Insight. 2021 Dec 22;6(24).
   PubMed Web of Science ®Google Scholar
• Kayamuro H, Yoshioka Y, Abe Y, et al. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol. 2010 Dec;84(24):12703–12712.
   PubMed Web of Science ®Google Scholar
• Zhong C, Liu F, Hajnik RJ, et al. Type I interferon promotes humoral immunity in viral vector vaccination. J Virol. 2021 Oct 27;95(22):e0092521.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020 Sep;21(9):1107–1118.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Hirahara K, Onodera A, et al. Th2 cells in health and disease. Annu Rev Immunol. 2017 Apr 26;35:53–84.
   PubMed Web of Science ®Google Scholar
• Walker JA, McKenzie ANJ. T(H)2 cell development and function. Nat Rev Immunol. 2018 Feb;18(2):121–133.
   PubMed Web of Science ®Google Scholar
• Raphael I, Joern RR, Forsthuber TG. Memory CD4(+) T cells in immunity and autoimmune diseases. Cells. 2020 Feb 25;9(3).
   PubMed Web of Science ®Google Scholar
• Hur JY, Frost GR, Wu X, et al. The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer's disease. Nature. 2020 Oct;586(7831):735–740.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang D, Zhu M, et al. Roles of SAMHD1 in antiviral defense, autoimmunity and cancer. Rev Med Virol. 2017 Jul;27(4).
   PubMed Web of Science ®Google Scholar
• Pizzolato G, Kaminski H, Tosolini M, et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11906–11915.
   PubMed Web of Science ®Google Scholar
• Bongen E, Vallania F, Utz PJ, et al. KLRD1-expressing natural killer cells predict influenza susceptibility. Genome Med. 2018 Jun 14;10(1):45.
   PubMedGoogle Scholar
• Escobar G, Mangani D, Anderson AC. T cell factor 1: A master regulator of the T cell response in disease. Sci Immunol. 2020 Nov 6;5(53).
   PubMed Web of Science ®Google Scholar
• Choi YS, Gullicksrud JA, Xing S, et al. LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6. Nat Immunol. 2015 Sep;16(9):980–990.
   PubMed Web of Science ®Google Scholar
• Mikhak Z, Fleming CM, Medoff BD, et al. STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells. J Immunol. 2006 Apr 15;176(8):4959–4967.
   PubMed Web of Science ®Google Scholar
• Majri SS, Fritz JM, Villarino AV, et al. STAT5B: a differential regulator of the life and death of CD4(+) effector memory T cells. J Immunol. 2018 Jan 1;200(1):110–118.
   PubMed Web of Science ®Google Scholar
• Powell MD, Read KA, Sreekumar BK, et al. Ikaros zinc finger transcription factors: regulators of cytokine signaling pathways and CD4(+) T helper cell differentiation. Front Immunol. 2019;10:1299.
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Gorman J, Anthony CS, et al. Structure of an N276-dependent HIV-1 neutralizing antibody targeting a rare V5 glycan hole adjacent to the CD4 binding site. J Virol. 2016 Nov 15;90(22):10220–10235.
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022 Feb;23(2):186–193.
   PubMed Web of Science ®Google Scholar
• Saad-Roy CM, Wagner CE, Baker RE, et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science. 2020;370(6518):811–818.
   PubMed Web of Science ®Google Scholar
• Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011 May 26;473(7348):523–527.
   PubMed Web of Science ®Google Scholar
• Ruterbusch M, Pruner KB, Shehata L, et al. In vivo CD4(+) T cell differentiation and function: revisiting the Th1/Th2 paradigm. Annu Rev Immunol. 2020 Apr 26;38:705–725.
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012 Jan 29;18(2):274–280.
   PubMed Web of Science ®Google Scholar
• White AD, Sarfas C, Sibley LS, et al. Protective efficacy of inhaled BCG vaccination against ultra-Low dose aerosol M. tuberculosis challenge in rhesus macaques. Pharmaceutics. 2020 Apr 25;12(5).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Mikami N, Wing JB, et al. Regulatory T cells and human disease. Annu Rev Immunol. 2020 Apr 26;38:541–566.
   PubMed Web of Science ®Google Scholar
• Song C, Pan W, Brown B, et al. Immune repertoire analysis of normal Chinese donors at different ages. Cell Prolif. 2022 Nov;55(11):e13311.
   PubMed Web of Science ®Google Scholar
• Patil VS, Madrigal A, Schmiedel BJ, et al. Precursors of human CD4(+) cytotoxic T lymphocytes identified by single-cell transcriptome analysis. Sci Immunol. 2018 Jan 19;3(19).
   PubMed Web of Science ®Google Scholar
• Xu J, Tang L, Wang Z, et al. MIR548P and TRAV39 are potential indicators of tumor microenvironment and novel prognostic biomarkers of esophageal squamous cell carcinoma. J Oncol. 2022;2022:3152114.
   PubMed Web of Science ®Google Scholar
• Ramasamy S, Subbian S. Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis. Clin Microbiol Rev. 2021 Jun 16;34(3).
   Web of Science ®Google Scholar
• Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 2022 Feb 1;8(1):10.
   PubMed Web of Science ®Google Scholar
• Rockman S, Lowther S, Camuglia S, et al. Intravenous immunoglobulin protects against severe pandemic influenza infection. EBioMedicine. 2017 May;19:119–127.
   PubMed Web of Science ®Google Scholar
• Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2006 Jan;208(2):270–282.
   PubMed Web of Science ®Google Scholar
• Leng L, Li M, Li W, et al. Sera proteomic features of active and recovered COVID-19 patients: potential diagnostic and prognostic biomarkers. Signal Transduct Target Ther. 2021 Jun 3;6(1):216.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan Q, Luo K, et al. Analysis of B cell receptor repertoires reveals key signatures of the systemic B cell response after SARS-CoV-2 infection. J Virol. 2022 Feb 23;96(4):e0160021.
   PubMed Web of Science ®Google Scholar
• Kim C, Ryu DK, Lee J, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021 Jan 12;12(1):288.
   PubMed Web of Science ®Google Scholar
• Andreano E, Nicastri E, Paciello I, et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021 Apr 1;184(7):1821–1835.e16.
   PubMed Web of Science ®Google Scholar
• Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.
   PubMed Web of Science ®Google Scholar
• Christian LM, Porter K, Karlsson E, et al. Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination. Vaccine. 2015 Jun 26;33(29):3360–3366.
   PubMed Web of Science ®Google Scholar
• Luo L, Liang W, Pang J, et al. Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. Cell Discov. 2021 Sep 28;7(1):89.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021 Aug;21(8):475–484.
   PubMed Web of Science ®Google Scholar
• Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443–473.
   PubMed Web of Science ®Google Scholar
• Ai J, Guo J, Zhang H, et al. Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling. Cell Discov. 2022 Oct 21;8(1):114.
   PubMed Web of Science ®Google Scholar